Nicardipine hydrochloride in essential hypertension‐a controlled study.

Asplund, Johan

doi:10.1111/j.1365-2125.1985.tb05153.x

Cited by 38 publications

(10 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dihydropyridine calcium blockers, rep resented by nifedipine and nicardipine, are widely used for the treatment of hypertensive disorders (1)(2)(3)(4)(5). However the clinical use fulness of these calcium blockers has been limited by dosage frequency because their durations of action are relatively short (6).…”

mentioning

confidence: 99%

Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker.

et al. 1989

View full text Add to dashboard Cite

Abstract-CS-905is a novel dihydropyridine calcium blocker. A single oral admin istration of CS-905 or nicardipine at doses of 0.3-3.0 mg/kg produced a dose dependent reduction of blood pressure in conscious SHR. CS-905, when adminis tered orally in conscious SHR, was more than 3 times as potent as nicardipine. Unlike the hypotensive effect of nicardipine, that of CS-905 has a gradual onset and is long-lasting, with little increase in heart rate. An intravenous administration of CS-905 also produced a hypotension with a slow onset and long duration in SHR, but CS-905 was 3 times less potent than nicardipine by intravenous administration. This difference may be attributed to the first pass effect, which was associated with nicardipine but not with CS-905. The blood pressure lowering effects of CS-905 was most potent in DOCA-salt hypertensive rats, followed by SHR, RHR and normotensive rats, in this order. CS-905 is expected to be an antihypertensive agent that is effective on a once a day regimen in clinical settings.

show abstract

mentioning

confidence: 99%

Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker.

et al. 1989

View full text Add to dashboard Cite

show abstract

“…Nicardipine was associated here with a significant increase in heart rate in Group C, but not in Groups A and B. Oral doses of nicardipine [7,25] or nifedipine [26,27] have been reported not to cause any increase in heart rate in patients with essential hypertension, whereas acute intravenous doses of these drugs [12,28] may increase the rate. It has been suggested that the baroreceptor might be reset so that the heart rate would return to normal after chronic treatment with them.…”

Section: Discussionmentioning

confidence: 93%

Renal effects of nicardipine, a calcium antagonist, in hypertensive type 2 (non-insulin-dependent) diabetic patients with and without nephropathy

Baba

Tomiyama

Murabayashi

et al. 1990

Eur J Clin Pharmacol

View full text Add to dashboard Cite

The renal effects of oral maintenance doses of nicardipine 60-120 mg/day have been studied in 18 hypertensive patients with Type 2 (non-insulin-dependent) diabetes mellitus: 6 with normoalbuminuria (urinary albumin excretion rate, AER less than 20 micrograms.min-1, Group A); 6 with incipient nephropathy, (AER 20-200 micrograms.min-1, Group B); and 6 with overt nephropathy (AER greater than 200 micrograms.min-1, Group C). Treatment for 4 weeks significantly lowered the systolic and diastolic blood pressures and reduced total renal vascular resistance in all three groups. Nicardipine increased renal blood flow significantly in Group C and slightly in Group B, and had no effect in Group A. Glomerular filtration rate remained unchanged in all three groups. It significantly reduced AER and the fractional clearance of albumin in Group B, whereas AER in Groups A and C was not altered. Plasma renin activity, aldosterone concentration, osmotic pressure, serum total protein and albumin concentrations and haemoglobin A1c level were similar in the control and nicardipine phases in all three groups. The results suggest that nicardipine may preserve renal function whilst having a concomitant hypotensive action in hypertensive Type 2 diabetic patients with normoalbuminuria and incipient nephropathy, and that the drug may improve renal blood flow in patients with overt nephropathy. The effect of the drug on urinary albumin excretion may deserve further investigation.

show abstract

“…This is in contrast to the experience with a similar dosage of nifedipine, which was effective, but significant side effects were frequent (7). The dosage employed in the present study has been used successfully in clinical trials in the treatment of ischemic heart disease and hypertension (33)(34)(35).…”

Section: Discussionmentioning

confidence: 99%

Nicardipine in the treatment of raynaud's phenomenon

Wigley

Wise

Malamet

et al. 1987

Arthritis & Rheumatism

View full text Add to dashboard Cite

A new calcium channel blocker, nicardipine, was studied for treatment of Raynaud's phenomenon in a double-blind, placebo-controlled, crossover trial during the winter months. Clinical response was assessed by a patient-kept diary of symptoms and finger systolic pressure that was measured at room temperature and during cold challenge. In vivo platelet activation was determined by measuring plasma levels of the plateletspecific proteins, beta-thromboglobulin and platelet factor 4. When treatment with placebo was compared with treatment with nicardipine, no significant differences were found in the namber of Raynaud's attacks per day, the severity of attacks, change in character in Raynaud's phenomenon, use of hands in winter months, patient assessment of medication or objective measurements of finger systolic pressure, and critical closing temperature. There was a reduction of plasma levels of beta-thromboglobulin and platelet factor 4 in the overall study group while taking nicardipine compared with that during the placebo period (mean change 5.0 f 2.4 ng/ml, P = 0.054, and 1.4 f 0.6 ng/ml, P < 0.01, respectively). These results demonstrate that while nicardipine was not effective in reducing the episodes of Raynaud's phenomenon, it did inhibit in vivo platelet activation. These findings suggest that platelet activation

show abstract

Nicardipine hydrochloride in essential hypertension‐a controlled study.

Cited by 38 publications

References 12 publications

Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker.

Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker.

Renal effects of nicardipine, a calcium antagonist, in hypertensive type 2 (non-insulin-dependent) diabetic patients with and without nephropathy

Nicardipine in the treatment of raynaud's phenomenon

Contact Info

Product

Resources

About